Education
About Us
Working with TipRanks
Follow Us
Amgen Inc (AMGN)
:AMGN
AMGN Stock Chart & Stats
$293.85
-$0.21(-0.08%)
At close: 4:00 PM EST
$293.85
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$253.30 - $335.88
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.60M
Market Cap
$157.42B
Enterprise Value$199.23B
Total Cash (Recent Filing)$8.03B
Total Debt (Recent Filing)$56.20B
Price to Earnings (P/E)23.9
Beta0.45
Next Earnings
Nov 04, 2025EPS Estimate
5.04Last Dividend Ex-Date
Aug 22, 2025Dividend Yield3.2%
Share Statistics
EPS (TTM)6.02
Shares Outstanding538,361,900
10 Day Avg. Volume2,525,667
30 Day Avg. Volume2,603,316
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue5.71
Enterprise Value/Gross Profit8.85
Enterprise Value/Ebitda12.53
Forecast
1Y Price Target
$322.59Price Target Upside9.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAMGN reported earnings per share significantly above consensus expectations, leading to an increase in full-year 2025 earnings guidance.
Regulatory ApprovalRepatha's label was approved for use in adults at increased risk for major adverse cardiovascular events, broadening its reach into the primary prevention space.
Revenue GrowthAmgen's Q2 results surpassed expectations for both total revenue and EPS, showing strong performance.
Bears Say
Market PerformanceThe trading price of Amgen is slightly above the analyst's price objective, indicating a potential overvaluation.
Product PerformanceSales of Enbrel significantly underperformed compared to consensus expectations, negatively impacting the overall sales figures.
R&D ExpensesThere is concern over increasing R&D expenses related to obesity, which could affect future margins and EPS.
Amgen News
AMGN FAQ
What was Amgen Inc’s price range in the past 12 months?
Amgen Inc lowest stock price was $253.30 and its highest was $335.88 in the past 12 months.
What is Amgen Inc’s market cap?
Amgen Inc’s market cap is $157.42B.
When is Amgen Inc’s upcoming earnings report date?
Amgen Inc’s upcoming earnings report date is Nov 04, 2025 which is in 19 days.
How were Amgen Inc’s earnings last quarter?
Amgen Inc released its earnings results on Aug 05, 2025. The company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.281 by $0.739.
Is Amgen Inc overvalued?
According to Wall Street analysts Amgen Inc’s price is currently Undervalued.
Does Amgen Inc pay dividends?
Amgen Inc pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.2%. See more information on Amgen Inc dividends here
What is Amgen Inc’s EPS estimate?
Amgen Inc’s EPS estimate is 5.04.
How many shares outstanding does Amgen Inc have?
Amgen Inc has 538,361,900 shares outstanding.
What happened to Amgen Inc’s price movement after its last earnings report?
Amgen Inc reported an EPS of $6.02 in its last earnings report, beating expectations of $5.281. Following the earnings report the stock price went down -5.133%.
Which hedge fund is a major shareholder of Amgen Inc?
Currently, no hedge funds are holding shares in AMGN
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$322.59 (9.78% Upside)
$322.59 (9.78% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.45%
12-Months-Change
Fundamentals
Return on Equity
99.14%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Amgen Inc
Amgen Inc. is a leading biotechnology company based in the United States, focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. Established in 1980, Amgen operates primarily in the biopharmaceutical sector, specializing in the areas of oncology, nephrology, rheumatology, and other serious diseases. The company is known for its core products including Enbrel, Neulasta, and Prolia, which are designed to treat a variety of medical conditions through advanced biotechnology techniques.
AMGN Company Deck
AMGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Amgen's Q2 2025 earnings call highlighted strong revenue and volume growth, driven by significant increases in sales of key products and a robust rare disease portfolio. The company also demonstrated progress in its R&D pipeline. However, challenges remain with pricing pressures and regulatory changes. Despite these challenges, the positive aspects of the call outweigh the negatives.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$322.59
▲(9.78% Upside)
Technical Analysis
Ownership Overview
0.19% Insiders
24.64% Mutual Funds
0.58% Other Institutional Investors
45.93% Public Companies and Individual Investors